31 study showed that giving Imfinzi (durvalumab) as adjuvant therapy for stage IB-IIIA non-small cell lung cancer (NSCLC ... dominance of MSD’s Keytruda (pembrolizumab) in metastatic disease.
Some results have been hidden because they may be inaccessible to you